Nektar Therapeutics (NKTR) Return on Invested Capital (2018 - 2025)
Historic Return on Invested Capital for Nektar Therapeutics (NKTR) over the last 15 years, with Q3 2025 value amounting to 3.21%.
- Nektar Therapeutics' Return on Invested Capital fell 8300.0% to 3.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.21%, marking a year-over-year decrease of 8300.0%. This contributed to the annual value of 1.1% for FY2024, which is 400.0% down from last year.
- Latest data reveals that Nektar Therapeutics reported Return on Invested Capital of 3.21% as of Q3 2025, which was down 8300.0% from 19.18% recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' Return on Invested Capital registered a high of 19.18% during Q2 2025, and its lowest value of 3.21% during Q3 2025.
- In the last 5 years, Nektar Therapeutics' Return on Invested Capital had a median value of 1.27% in 2024 and averaged 0.31%.
- Data for Nektar Therapeutics' Return on Invested Capital shows a peak YoY increase of 207600bps (in 2025) and a maximum YoY decrease of -17900bps (in 2025) over the last 5 years.
- Quarter analysis of 5 years shows Nektar Therapeutics' Return on Invested Capital stood at 0.6% in 2021, then tumbled by -62bps to 0.97% in 2022, then plummeted by -86bps to 1.81% in 2023, then fell by -6bps to 1.92% in 2024, then plummeted by -68bps to 3.21% in 2025.
- Its last three reported values are 3.21% in Q3 2025, 19.18% for Q2 2025, and 3.07% during Q1 2025.